<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026125</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0443</org_study_id>
    <secondary_id>2021-000727-12</secondary_id>
    <nct_id>NCT05026125</nct_id>
  </id_info>
  <brief_title>Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients</brief_title>
  <acronym>OBEREM</acronym>
  <official_title>Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients With Two Doses of Remifentanil: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the condition of orotracheal intubation in obese patients undergoing&#xD;
      an elective bariatric surgery without the use of neuromuscular blocking agents.&#xD;
&#xD;
      During the induction of general anesthesia, Propofol - Remifentanil combination will be used.&#xD;
&#xD;
      The patients will be randomized in 2 groups with different doses of Remifentanil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of obesity increases steadily. For anesthesiologists, the airway management of&#xD;
      obese patients is known to be difficult and at risk. Tracheal intubation needs to be&#xD;
      successful quickly. Neuromuscular blocking agents allow this option but with a risk of&#xD;
      anaphylaxis and respiratory complications. In fact, for many surgical procedures those drugs&#xD;
      are not necessary.&#xD;
&#xD;
      Numerous studies in non-obese patients with the combination of Remifentanil and Propofol have&#xD;
      shown adequate conditions for tracheal intubation without neuromuscular blocking drugs. This&#xD;
      combination has never been studied in obese patient.&#xD;
&#xD;
      After randomization, induction of general anesthesia will be performed with 2,5 mg/kg of&#xD;
      Propofol in association with either 3 µg/kg of Ideal Body Weight of Remifentanil, or 3 µg/kg&#xD;
      + 30% of Ideal Body Weight of Remifentanil.&#xD;
&#xD;
      Minutes after the induction, orotracheal intubation will be performed, and the Intubation&#xD;
      Difficulty Scale recorded.&#xD;
&#xD;
      Other data on hemodynamic, respiratory and airway management will be are collected during the&#xD;
      surgery.&#xD;
&#xD;
      In the Post Anaesthetic Care Unit (PACU),Any symptoms of traumatic airway management or&#xD;
      aspiration are collected.&#xD;
&#xD;
      Those data will be again looked for and collected on the day of the patient's discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, controlled, double blinded and monocentric Pilot Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>with randomization envelopes opened by the care provider</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of good to excellent conditions of intubation</measure>
    <time_frame>Day 0</time_frame>
    <description>percentage of good to excellent conditions of intubation in obese patients using the Intubation Difficulty Scale (IDS). The IDS is graded in the operating theater during the induction of general anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic events day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Hemodynamic events day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic events day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Hemodynamic events day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory events day 0</measure>
    <time_frame>day 0</time_frame>
    <description>Respiratory events day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory events day 3</measure>
    <time_frame>day 3</time_frame>
    <description>Respiratory events day 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Intubation Complication</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 μg/kg (Ideal Body Weight) of Remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Injection</intervention_name>
    <description>Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Injection plus 30%</intervention_name>
    <description>Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 and under 60 years old.&#xD;
&#xD;
          -  ASA score ≤ 3&#xD;
&#xD;
          -  Elective bariatric surgery for patient with BMI between 35 and 60 or elective revision&#xD;
             of a bariatric surgery for patient with a BMI over 30.&#xD;
&#xD;
          -  Patient with a written consent obtained with accurate information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with risk of aspiration&#xD;
&#xD;
          -  Difficult airway known (Cormack score 3 ou 4).&#xD;
&#xD;
          -  Opioids addiction.&#xD;
&#xD;
          -  Alcoholism&#xD;
&#xD;
          -  Chronic use of Opioids&#xD;
&#xD;
          -  Confirmed Allergy to Propofol or Remifentanil&#xD;
&#xD;
          -  Severe chronic hepatic, kidney or respiratory failure&#xD;
&#xD;
          -  Patient already enrolled in another clinical study interfering with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Géraldine FAURE, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Géraldine FAURE, MD</last_name>
    <phone>05 61 32 30 23</phone>
    <phone_ext>+33</phone_ext>
    <email>faure.geraldine@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre GOUDY, MD</last_name>
    <phone_ext>+33</phone_ext>
    <email>goudy.p@chu-toulouse.fr</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tracheal intubation</keyword>
  <keyword>obese patient</keyword>
  <keyword>neuromuscular blocking agent</keyword>
  <keyword>remifentanil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

